使用[68Ga]pentixather PET/CT对新诊断的多发性骨髓瘤进行趋化因子受体 4 靶向 PET/CT：与[68Ga]pentixafor PET/CT 的比较研究。

IF 3 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Molecular Imaging and Biology Pub Date : 2024-09-20 DOI:10.1007/s11307-024-01953-7

Qiao Yang, Fujing Zhang, Zhixin Hao, Junling Zhuang, Li Huo

{"title":"使用[68Ga]pentixather PET/CT对新诊断的多发性骨髓瘤进行趋化因子受体 4 靶向 PET/CT：与[68Ga]pentixafor PET/CT 的比较研究。","authors":"Qiao Yang, Fujing Zhang, Zhixin Hao, Junling Zhuang, Li Huo","doi":"10.1007/s11307-024-01953-7","DOIUrl":null,"url":null,"abstract":"Purpose: This study aimed to compare the detection rate of [68Ga]pentixather PET/CT and [68Ga]pentixafor PET/CT in newly diagnosed multiple myeloma (NDMM) patients, and to explore the value of [68Ga]pentixather PET/CT for tumor load assessment.Methods: Nineteen NDMM Patients were prospectively recruited and underwent both [68Ga]pentixather PET/CT and [68Ga]pentixafor PET/CT. A positive PET scan was defined as the presence of PET-positive focal bone lesions, paraskeletal disease, extramedullary plasmacytoma, or diffuse bone marrow uptake. Lesion numbers, SUVmax and PET-related tumor burden values were compared. The correlations between PET-related tumor burden and clinical risk stratification were analyzed.Results: [68Ga]pentixather PET/CT showed a tendency of higher positive rate compared with [68Ga]pentixafor PET/CT [94.7% (18/19) vs. 78.9% (15/19), p > 0.05]. Among 14 patients with 151 matched focal bone lesions, [68Ga]pentixather PET detected more or equal number of lesions in 13 patients, and demonstrated higher uptake value than 68 Ga-pentixafor PET [SUVmax, 16.8 (9.0, 23.8) vs. 13.4 (6.5, 20.4), p < 0.001]. For PET related-tumor burden, positive correlations of total bone marrow uptake (TBmU) (r = 0.9540, p < 0.0001) and SUVmean of total bone marrow (r = 0.9632, p < 0.0001) in two PET scans were observed. Higher TBmU [7864.9 (5549.2, 11,616.2) vs. 5383.4(4102.7, 11,041.8), p < 0.001], SUVmean of total bone marrow [1.4 (1.1, 2.2) vs. 1.1 (0.7, 2.1), p < 0.001] were demonstrated on [68Ga]pentixather PET than [68Ga]pentixafor PET. And the level of TBmU in [68Ga]pentixather PET and [68Ga]pentixafor PET were both elevated in Durie-Salmon Staging (DSS) III than DSS I (p < 0.01).Conclusions: [68Ga]pentixather PET/CT performed a non-inferior capability for tumor detection compared to [68Ga]pentixafor PET/CT in NDMM patients. [68Ga]pentixather PET/CT can assess tumor load in MM patients and depict a significantly higher PET-related total tumor burden than [68Ga]pentixafor PET/CT.","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Chemokine Receptor 4-Targeted PET/CT with [68Ga]pentixather in Newly Diagnosed Multiple Myeloma: a Comparative Study with [68Ga]pentixafor PET/CT.\",\"authors\":\"Qiao Yang, Fujing Zhang, Zhixin Hao, Junling Zhuang, Li Huo\",\"doi\":\"10.1007/s11307-024-01953-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: This study aimed to compare the detection rate of [68Ga]pentixather PET/CT and [68Ga]pentixafor PET/CT in newly diagnosed multiple myeloma (NDMM) patients, and to explore the value of [68Ga]pentixather PET/CT for tumor load assessment.Methods: Nineteen NDMM Patients were prospectively recruited and underwent both [68Ga]pentixather PET/CT and [68Ga]pentixafor PET/CT. A positive PET scan was defined as the presence of PET-positive focal bone lesions, paraskeletal disease, extramedullary plasmacytoma, or diffuse bone marrow uptake. Lesion numbers, SUVmax and PET-related tumor burden values were compared. The correlations between PET-related tumor burden and clinical risk stratification were analyzed.Results: [68Ga]pentixather PET/CT showed a tendency of higher positive rate compared with [68Ga]pentixafor PET/CT [94.7% (18/19) vs. 78.9% (15/19), p > 0.05]. Among 14 patients with 151 matched focal bone lesions, [68Ga]pentixather PET detected more or equal number of lesions in 13 patients, and demonstrated higher uptake value than 68 Ga-pentixafor PET [SUVmax, 16.8 (9.0, 23.8) vs. 13.4 (6.5, 20.4), p < 0.001]. For PET related-tumor burden, positive correlations of total bone marrow uptake (TBmU) (r = 0.9540, p < 0.0001) and SUVmean of total bone marrow (r = 0.9632, p < 0.0001) in two PET scans were observed. Higher TBmU [7864.9 (5549.2, 11,616.2) vs. 5383.4(4102.7, 11,041.8), p < 0.001], SUVmean of total bone marrow [1.4 (1.1, 2.2) vs. 1.1 (0.7, 2.1), p < 0.001] were demonstrated on [68Ga]pentixather PET than [68Ga]pentixafor PET. And the level of TBmU in [68Ga]pentixather PET and [68Ga]pentixafor PET were both elevated in Durie-Salmon Staging (DSS) III than DSS I (p < 0.01).Conclusions: [68Ga]pentixather PET/CT performed a non-inferior capability for tumor detection compared to [68Ga]pentixafor PET/CT in NDMM patients. [68Ga]pentixather PET/CT can assess tumor load in MM patients and depict a significantly higher PET-related total tumor burden than [68Ga]pentixafor PET/CT.\",\"PeriodicalId\":18760,\"journal\":{\"name\":\"Molecular Imaging and Biology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular Imaging and Biology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11307-024-01953-7\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging and Biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11307-024-01953-7","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

摘要

目的：本研究旨在比较[68Ga]pentixather PET/CT和[68Ga]pentixafor PET/CT在新诊断多发性骨髓瘤（NDMM）患者中的检出率，并探讨[68Ga]pentixather PET/CT在肿瘤负荷评估中的价值：前瞻性招募了19名NDMM患者，对其进行了[68Ga]pentixather PET/CT和[68Ga]pentixafor PET/CT检查。PET扫描阳性的定义是存在PET阳性的局灶性骨病变、寄生虫病、髓外浆细胞瘤或弥漫性骨髓摄取。对病灶数量、SUVmax 和 PET 相关肿瘤负荷值进行了比较。分析了PET相关肿瘤负荷与临床风险分层之间的相关性：与[68Ga]pentixafor PET/CT相比，[68Ga]pentixather PET/CT显示出更高的阳性率[94.7% (18/19) vs. 78.9% (15/19)，P > 0.05]。在14例151个匹配的局灶性骨病变患者中，[68Ga]pentixather PET在13例患者中检测到更多或相同数量的病变，并显示出比68Ga-pentixafor PET更高的摄取值[SUVmax，16.8 (9.0, 23.8) vs. 13.4 (6.5, 20.4)，p 68Ga]pentixather PET高于[68Ga]pentixafor PET。而[68Ga]pentixather PET 和[68Ga]pentixafor PET 中的 TBmU 水平在 Durie-Salmon 分期（DSS）III 中均高于 DSS I（P与[68Ga]pentixafor PET/CT相比，[68Ga]pentixather PET/CT在NDMM患者中的肿瘤检测能力并不亚于[68Ga]pentixafor PET/CT。68Ga]pentixather正电子发射计算机断层显像/CT可评估MM患者的肿瘤负荷，与[68Ga]pentixafor正电子发射计算机断层显像/CT相比，[68Ga]pentixather正电子发射计算机断层显像/CT描绘的与正电子发射计算机断层显像相关的总肿瘤负荷明显更高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Chemokine Receptor 4-Targeted PET/CT with [⁶⁸Ga]pentixather in Newly Diagnosed Multiple Myeloma: a Comparative Study with [⁶⁸Ga]pentixafor PET/CT.

Purpose: This study aimed to compare the detection rate of [⁶⁸Ga]pentixather PET/CT and [⁶⁸Ga]pentixafor PET/CT in newly diagnosed multiple myeloma (NDMM) patients, and to explore the value of [⁶⁸Ga]pentixather PET/CT for tumor load assessment.

Methods: Nineteen NDMM Patients were prospectively recruited and underwent both [⁶⁸Ga]pentixather PET/CT and [⁶⁸Ga]pentixafor PET/CT. A positive PET scan was defined as the presence of PET-positive focal bone lesions, paraskeletal disease, extramedullary plasmacytoma, or diffuse bone marrow uptake. Lesion numbers, SUVmax and PET-related tumor burden values were compared. The correlations between PET-related tumor burden and clinical risk stratification were analyzed.

Results: [⁶⁸Ga]pentixather PET/CT showed a tendency of higher positive rate compared with [⁶⁸Ga]pentixafor PET/CT [94.7% (18/19) vs. 78.9% (15/19), p > 0.05]. Among 14 patients with 151 matched focal bone lesions, [⁶⁸Ga]pentixather PET detected more or equal number of lesions in 13 patients, and demonstrated higher uptake value than ⁶⁸ Ga-pentixafor PET [SUVmax, 16.8 (9.0, 23.8) vs. 13.4 (6.5, 20.4), p < 0.001]. For PET related-tumor burden, positive correlations of total bone marrow uptake (TBmU) (r = 0.9540, p < 0.0001) and SUVmean of total bone marrow (r = 0.9632, p < 0.0001) in two PET scans were observed. Higher TBmU [7864.9 (5549.2, 11,616.2) vs. 5383.4(4102.7, 11,041.8), p < 0.001], SUVmean of total bone marrow [1.4 (1.1, 2.2) vs. 1.1 (0.7, 2.1), p < 0.001] were demonstrated on [⁶⁸Ga]pentixather PET than [⁶⁸Ga]pentixafor PET. And the level of TBmU in [⁶⁸Ga]pentixather PET and [⁶⁸Ga]pentixafor PET were both elevated in Durie-Salmon Staging (DSS) III than DSS I (p < 0.01).

Conclusions: [⁶⁸Ga]pentixather PET/CT performed a non-inferior capability for tumor detection compared to [⁶⁸Ga]pentixafor PET/CT in NDMM patients. [⁶⁸Ga]pentixather PET/CT can assess tumor load in MM patients and depict a significantly higher PET-related total tumor burden than [⁶⁸Ga]pentixafor PET/CT.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Molecular Imaging and Biology 医学-核医学

CiteScore

6.90

自引率

3.20%

发文量

审稿时长

3 months

期刊介绍： Molecular Imaging and Biology (MIB) invites original contributions (research articles, review articles, commentaries, etc.) on the utilization of molecular imaging (i.e., nuclear imaging, optical imaging, autoradiography and pathology, MRI, MPI, ultrasound imaging, radiomics/genomics etc.) to investigate questions related to biology and health. The objective of MIB is to provide a forum to the discovery of molecular mechanisms of disease through the use of imaging techniques. We aim to investigate the biological nature of disease in patients and establish new molecular imaging diagnostic and therapy procedures. Some areas that are covered are: Preclinical and clinical imaging of macromolecular targets (e.g., genes, receptors, enzymes) involved in significant biological processes. The design, characterization, and study of new molecular imaging probes and contrast agents for the functional interrogation of macromolecular targets. Development and evaluation of imaging systems including instrumentation, image reconstruction algorithms, image analysis, and display. Development of molecular assay approaches leading to quantification of the biological information obtained in molecular imaging. Study of in vivo animal models of disease for the development of new molecular diagnostics and therapeutics. Extension of in vitro and in vivo discoveries using disease models, into well designed clinical research investigations. Clinical molecular imaging involving clinical investigations, clinical trials and medical management or cost-effectiveness studies.